Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04872790
Status:
RECRUITING
Last Update Posted:
2023-12-20
First Post:
2021-03-19
Brief Title:
Venetoclax Dasatinib Prednisone Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Sponsor:
OHSU Knight Cancer Institute
Organization:
OHSU Knight Cancer Institute
Organization Data
Organization:
OHSU Knight Cancer Institute
Class:
OTHER
Study ID:
STUDY00022691
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
OHSU Knight Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Jessica Leonard
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
OHSU Knight Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Oregon Health and Science University | OTHER |
| AbbVie | INDUSTRY |